Dashboard
Low Debt Company with Strong Long Term Fundamental Strength
- Healthy long term growth as Net Sales has grown by an annual rate of 13.95% and Operating profit at 16.92%
- Company has a low Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Capital Employed (avg) of 15.11% signifying high profitability per unit of total capital (equity and debt)
Negative results in Jun 25
With ROE of 18.22%, it has a attractive valuation with a 4.17 Price to Book Value
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 6,910,034 Million (Large Cap)
23.00
NA
0.00%
-0.24
18.74%
4.38
Total Returns (Price + Dividend) 
Daiichi Sankyo Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Daiichi Sankyo Stock Hits Day Low of JPY 3,562 Amid Price Pressure
Daiichi Sankyo Co. faced a challenging trading session, with its stock price declining significantly. Over the past year, the company has underperformed compared to the Japan Nikkei 225. Despite short-term setbacks, Daiichi Sankyo shows strong long-term growth potential, with solid profitability metrics and a low debt-to-equity ratio.
Read More
Daiichi Sankyo Hits Day Low of JPY 3,800 Amid Price Pressure
Daiichi Sankyo Co. faced a decline on October 30, 2025, amid ongoing market challenges. The stock has decreased significantly over the past week and year-to-date, contrasting with the Japan Nikkei 225's performance. Despite short-term struggles, the company shows strong long-term growth potential and solid financial metrics.
Read More
Daiichi Sankyo Stock Hits Day Low Amid Price Pressure, Closes at JPY 3,837.00
Daiichi Sankyo Co. faced a decline on October 29, 2025, amid ongoing market challenges. Despite underperforming against the Japan Nikkei 225 index over three years, the company shows strong long-term fundamentals, with notable growth in net sales and operating profit, alongside a solid financial position.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 4 Foreign Institutions (0.0%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 8.81% vs 24.32% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 0.14% vs 49.76% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 17.77% vs 25.28% in Mar 2024
YoY Growth in year ended Mar 2025 is 47.13% vs 84.10% in Mar 2024






